Acquisition Announced

Eli Lilly and Company acquisition of Kelonia Therapeutics

US$7bn consideration

Announced 20 Apr 2026

Advisers

Target
Kelonia Therapeutics
Acquirer
Eli Lilly and Company
Target based in
United States (unverified)
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Cell Therapy, Oncology

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.